Table 4.
The impact of probiotic intervention on changes in IBS-SSS scores.
| Groups | Baseline | After 4-Week Intervention | After 8-Week Intervention | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Change from Baseline | p-Value within-Group |
p-Value Comparison with Placebo |
Mean ± SD | Change from Baseline | p-Value within-Group |
p-Value Comparison with Placebo |
|
| Total IBS-SSS | |||||||||
| Probiotic | 339.6 ± 76.8 | 235.4 ± 77.9 | −104.2 ± 69.1 | <0.00001 | 0.159 | 173.8 ± 60.9* | −165.8 ± 78.9 | <0.00001 | 0.005 |
| Placebo | 325.9 ± 50.7 | 250.4 ± 60.9 | −75.5 ± 69.5 | <0.00001 | 220.3 ± 55.7 | −105.6 ± 60.2 | <0.00001 | ||
| IBS-SSS 1 (the severity of pain) | |||||||||
| Probiotic | 63.0 ± 21.8 | 42.0 ± 18.7 | −21.0 ± 21.3 | <0.00001 | 0.136 | 33.0 ± 13.9 | −30.0 ± 22.8 | <0.00001 | 0.015 |
| Placebo | 55.4 ± 19.9 | 44.6 ± 16.8 | −10.9 ± 19.7 | 0.027 | 42.4 ± 17.6 | −13.0 ± 19.7 | 0.009 | ||
| IBS-SSS 2 (the frequency of pain) | |||||||||
| Probiotic | 43.0 ± 22.3 | 29.0 ± 22.4 | −14.0 ± 27.1 | 0.006 | 0.211 | 18.0 ± 19.8 | −25.0 ± 27.9 | 0.0003 | 0.105 |
| Placebo | 33.7 ± 20.8 | 33.7 ± 26.6 | −1.1 ± 32.4 | 0.699 | 22.8 ± 21.2 | −10.9 ± 25.9 | 0.065 | ||
| IBS-SSS 3 (the severity of flatulence) | |||||||||
| Probiotic | 58.0 ± 31.2 | 40.0 ± 25.0 | −18.0 ± 30.2 | 0.01 | 0.165 | 29.0 ± 20.0 | −29.0 ± 22.4 | <0.00001 | 0.594 |
| Placebo | 66.3 ± 26.8 | 38.0 ± 24.8 | −28.3 ± 29.5 | 0.0004 | 35.9 ± 19.7 | −30.4 ± 21.3 | <0.00001 | ||
| IBS-SSS 4 (dissatisfaction with bowel habit) | |||||||||
| Probiotic | 86.4±17.0 | 64.8 ± 18.0 | −21.6 ± 23.5 | 0.0002 | 0.933 | 47.5 ± 19.2 | −38,88 ± 23.0 | <0.00001 | 0.526 |
| Placebo | 88.2 ± 16.5 | 69.0 ± 17.3 | −19.1 ± 24.6 | 0.003 | 57.4 ± 14.8 | −30.8 ± 24.6 | <0.00001 | ||
| IBS-SSS 5 (quality of life) | |||||||||
| Probiotic | 89.2 ± 18.8 | 59.6 ± 23.6 | −29.6 ± 22.3 | <0.00001 | 0.090 | 46.3 ± 21.5 * | −42.9 ± 26.5 | <0.00001 | 0.016 |
| Placebo | 82.3 ± 20.0 | 66.1 ± 17.5 | −16.2 ± 22.3 | 0.002 | 61.8 ± 18.3 | −20.5 ± 26.3 | 0.002 | ||
IBS symptom severity was evaluated with the use of the IBS-SSS at baseline and after 4 and 8 weeks of treatment. A score reduction corresponded to symptom amelioration. The results are shown as a mean ± standard deviation (SD). Presented p-values are for changes in IBS-SSS scores. p < 0.05 represents statistically significant differences. * statistically significant differences in means between the probiotic and placebo groups.